SPDR Advertisement SureTrader Stock Hero Advertisement SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences >

Biotech Values

RSS Feed
      Hide Sticky   Hide Intro
Moderator: DewDiligence Assistants: Biowatch
Search This Board:
Last Post: 3/6/2015 10:20:31 PM - Followers: 1215 - Board type: Free - Posts Today: 84
PostSubject
#188313  Sticky Note New Survey: Did ABBV overpay for PCYC? DewDiligence 03/06/15 07:35:34 PM
#188309  Sticky Note Re: ABBV-PCYC post-mortem DewDiligence 03/06/15 06:53:16 PM
#188262  Sticky Note FDA approves NVS’ Zarxio (NeupogenFoB), the first FDA DewDiligence 03/06/15 09:30:16 AM
#188252  Sticky Note I attended the ENTA [annual meeting] also, and DewDiligence 03/06/15 08:58:15 AM
#188221  Sticky Note OREX—I tweeted yesterday that the MACE risk reduction DewDiligence 03/05/15 06:11:37 PM
#188198  Sticky Note BARRON'S - After Pharmacyclics, Who’s Next in Biotech M&A? floblu14 03/05/15 01:03:08 PM
#188321   To try to compare the value of a jbog 03/06/15 10:20:31 PM
#188320   re: ARQL bladerunner1717 03/06/15 09:32:49 PM
#188319   ENTA/ARQLAt the company AM (annual meeting) Enta's CEO mcbio 03/06/15 08:53:28 PM
#188318   'mcbio, At the company AM (annual meeting) Enta's CEO caravon 03/06/15 08:48:43 PM
#188317   ENTA’s preclinical NASH candidates are “10-500 times as mcbio 03/06/15 08:25:30 PM
#188316   ENTA—an interesting development would be a cylophilin inhibitor DewDiligence 03/06/15 07:48:25 PM
#188315   Animal models of NASH: DewDiligence 03/06/15 07:44:45 PM
#188314   Answer to quiz in #msg-111171703: ABBV’s 10-K contains DewDiligence 03/06/15 07:41:44 PM
#188313   New Survey: Did ABBV overpay for PCYC? DewDiligence 03/06/15 07:35:34 PM
#188312   CNAT -8% today—investors are evidently assuming the worst DewDiligence 03/06/15 07:19:56 PM
#188311   ENTA’s preclinical NASH candidates are “10-500 times as DewDiligence 03/06/15 07:14:33 PM
#188310   ENTAI interpret this to mean that the FXR mcbio 03/06/15 06:57:39 PM
#188309   Re: ABBV-PCYC post-mortem DewDiligence 03/06/15 06:53:16 PM
#188308   They could also attack it with nucular medicine. LOL GrthzGd 03/06/15 06:04:13 PM
#188307   EGRX files $200M shelf registration: DewDiligence 03/06/15 05:34:15 PM
#188306   FDA approves Astellas’ Cresemba for fungal infections: DewDiligence 03/06/15 04:48:38 PM
#188305   I think many people don't understand the seriousness jq1234 03/06/15 04:02:40 PM
#188304   SQNM > NIPT Tests Find Cancer in Some biocqr 03/06/15 02:55:37 PM
#188303   Dew, apologies for "regiment" on the other board. DewDiligence 03/06/15 02:47:50 PM
#188302   My question was if anyone has a scenario DewDiligence 03/06/15 02:47:35 PM
#188301   SQNM > NIH Director Hails “Stunning Case” as biocqr 03/06/15 02:47:30 PM
#188300   Makes sense. CEO Rosa has said in past MrDanMan 03/06/15 02:05:24 PM
#188299   DRRX: +24% @ $1.66 as I write .Any north40000 03/06/15 02:00:25 PM
#188298   As long as the deaths had nothing to 3DPrintInvestor 03/06/15 01:56:21 PM
#188297   SSH 25% does seem overblown. How do you MrDanMan 03/06/15 01:54:12 PM
#188296   my pleasure and thank you dewophile 03/06/15 01:44:53 PM
#188295   Yes, but the end result is the same 3DPrintInvestor 03/06/15 01:41:58 PM
#188294   3dp - I am confused? I thought nowlurking 03/06/15 01:34:33 PM
#188293   Would probably become an industry standard if their 3DPrintInvestor 03/06/15 01:27:04 PM
#188292   Bought a little also. I was never nowlurking 03/06/15 01:24:34 PM
#188291   As is SYN!! mathew633 03/06/15 12:57:37 PM
#188290   This is a good map o 03/06/15 12:51:34 PM
#188289   >>how releasing interim result improperly could bias final result biomaven0 03/06/15 12:46:36 PM
#188287   I made some $$$ from it. Bought 12K linhdtu 03/06/15 12:26:45 PM
#188286   Zarxio 2nd addendum—This product is called Zarzio (with DewDiligence 03/06/15 12:20:31 PM
#188285   I should’ve picked AMRN in the 2015 SI DewDiligence 03/06/15 12:13:31 PM
#188284   BLUE & KITE showing amazing strength in the kei 03/06/15 12:09:00 PM
#188283   ~ AMRN $1.71 please do not worry, dew..its kei 03/06/15 12:06:40 PM
#188282   THOR similar trial right now is on clinical RealGenius 03/06/15 12:03:07 PM
#188281   I don't know. 3DPrintInvestor 03/06/15 11:52:49 AM
#188280   Do you recall if THOR went through similar nowlurking 03/06/15 11:37:33 AM
#188279   In that $35 PT, Barclays gives ABBV peak Rocky3 03/06/15 11:20:16 AM
#188278   You can also google HCV genotype map, willyw 03/06/15 11:19:57 AM
#188277   Sorry if this info is somewhere already, but pollyvonwog 03/06/15 11:15:19 AM
#188276   I buy fear and sell greed- so am 3DPrintInvestor 03/06/15 11:05:33 AM
#188275   …for SSH to take a 25% or so DewDiligence 03/06/15 11:04:52 AM
#188274   $SSH as a former manager of a cardiovascular 3DPrintInvestor 03/06/15 11:01:34 AM
#188273   agree other issues w the report as well dewophile 03/06/15 10:55:10 AM
#188272   In that $35 PT, Barclays gives ABBV peak pollyvonwog 03/06/15 10:28:53 AM
#188268   Actually, I took the subway, and I accept GrthzGd 03/06/15 09:58:14 AM
PostSubject